A total of 914 patients with successful drug-eluting stent ( DES ) implantation were randomly assigned to dual antiplatelet therapy ( DAT ; aspirin and clopidogrel , n = 457 ) or to triple antiplatelet therapy ( TAT ; DAT with cilostazol , n = 457 ) .